Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Dev Regulatory News (FDEV)

Share Price Information for Frontier Dev (FDEV)

Share Price is delayed by 15 minutes
Get Live Data
464.50    3.00 (0.65%)
Bid:
462.50
Ask:
465.50
Spread: 3.00 (0.649%)
Market Cap: £161.34m
FDEV Live PriceLast checked at - London Stock Exchange

Intraday Frontier Dev Share Chart

Elite: Dangerous Alpha testing begins in December

18 Oct 2013 07:00

RNS Number : 8107Q
Frontier Developments PLC
18 October 2013
 



18 October 2013

 

Frontier Developments plc

 

Elite: Dangerous - Alpha testing to begin in December 2013

 

 

Cambridge, UK. Frontier Developments plc (AIM: FDEV, "Frontier" or the "Company"), a leading developer of video games with studios in Cambridge, UK and Halifax, Canada, today revealed that eligible backers of Elite: Dangerous will be able to get their first taste of the game with the start of the Alpha test phase in December 2013, as expected.

 

The Alpha phase will begin with a combat test build - testing the combat systems in a close-to-final form.

 

At the end of 2012, Frontier raised £1.6 million via Kickstarter, the crowd funding service, and via its own website. The funds were raised specifically to develop Elite: Dangerous - the latest sequel to the Elite game that CEO David Braben originally co-authored, published in 1984. Backers eligible to access the Alpha test phase in December 2013 are those who contributed £200 or more to develop Elite: Dangerous.

 

 

Enquiries:

Frontier Developments

+44 (0)1223 394 300

David Braben, CEO

David Walsh, COO

Neil Armstrong, CFO

Canaccord Genuity

+44 (0) 207 523 8000

Simon Bridges/Cameron Duncan

College Hill

+44 (0) 20 7457 2020

Kay Larsen/Adrian Duffield

 

 

About Frontier Developments

 

Frontier was founded in 1994 by David Braben, co-author of the seminal Elite game. The Group has 227 full-time employees and operations in Cambridge, UK and Halifax, Nova Scotia, Canada. Frontier has a proven track record of software technology development and innovation spanning several decades of rapid technological change. Frontier has leveraged its technology to develop innovative videogames across a wide variety of different game genres and platforms, and has established relationships with globally renowned partners.

 

At the end of 2012, Frontier also raised £1.6 million via Kickstarter, the crowd funding service. The funds were raised specifically to develop Elite: Dangerous - the latest sequel to the Elite game that CEO David Braben originally co-authored, published in 1984. Elite was one of the first home computer games to use 3D graphics and the first to employ an open-world 'sandbox' gameplay model. Its revolutionary 3D graphics ensured that the game created the modern space flight simulation genre and influenced gaming as a whole.

 

About Cobra

Frontier's Cobra software technology has been developed and evolved since 1988. Initially conceived as a solution for the problem of easily porting the same game across different target hardware devices, Cobra today supports multi-core CPU and GPU architectures of PC, console, tablet and smartphone with a modular, high performance system offering of state of the art efficiency and visual fidelity that is applicable across a wide range of game genres.

 

Cobra incorporates a framework which enables rapid development of powerful game creation tools, which offer the ability to view, tweak and review changes to content (e.g. animations, audio, 3D models etc.) on target platforms in a live game session running on that platform, without the intervention of a programmer.

 

For more details on Cobra see http://www.frontier.co.uk/our_technology/

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADDLFFXBFFFBQ
Date   Source Headline
1st Jun 202612:05 pmRNSEBT Share Purchase
28th May 20262:30 pmRNS-RPlanet Zoo 2 Announced
22nd May 202611:26 amRNS-RWarhammer 40,000: Chaos Gate – Deathwatch Revealed
22nd May 20269:16 amRNSHolding(s) in Company
19th May 20265:47 pmRNSHolding(s) in Company
18th May 202610:48 amRNSEBT Share Purchase
12th May 20267:00 amRNSTrading Update - FY26 Revenue & Profit Upgraded
23rd Apr 20267:00 amRNSCompletion of Share Buyback Programme
23rd Apr 20267:00 amRNSDirector/PDMR Shareholding
23rd Apr 20267:00 amRNSTransaction in Own Shares
22nd Apr 202611:05 amRNSHolding(s) in Company
22nd Apr 20267:00 amRNSDirector/PDMR Shareholding
22nd Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
17th Apr 20267:00 amRNSDirector/PDMR Shareholding
17th Apr 20267:00 amRNSTransaction in Own Shares
16th Apr 20267:00 amRNSDirector/PDMR Shareholding
16th Apr 20267:00 amRNSTransaction in Own Shares
15th Apr 20267:00 amRNSDirector/PDMR Shareholding
15th Apr 20267:00 amRNSTransaction in Own Shares
14th Apr 20267:00 amRNSDirector/PDMR Shareholding
14th Apr 20267:00 amRNSTransaction in Own Shares
10th Apr 20267:00 amRNSDirector/PDMR Shareholding
10th Apr 20267:00 amRNSTransaction in Own Shares
9th Apr 20267:00 amRNSDirector/PDMR Shareholding
8th Apr 20267:00 amRNSDirector/PDMR Shareholding
8th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20267:00 amRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSDirector/PDMR Shareholding
2nd Apr 20267:00 amRNSTransaction in Own Shares
1st Apr 20267:00 amRNSDirector/PDMR Shareholding
1st Apr 20267:00 amRNSTransaction in Own Shares
31st Mar 20267:00 amRNSDirector/PDMR Shareholding
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:00 amRNSDirector/PDMR Shareholding
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSDirector/PDMR Shareholding
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20267:00 amRNSDirector/PDMR Shareholding
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 20267:00 amRNSDirector/PDMR Shareholding
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSDirector/PDMR Shareholding
24th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20267:00 amRNSDirector/PDMR Shareholding
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSDirector/PDMR Shareholding
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 20267:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.